Past Issues – Page 6 – The Cancer Letter

Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 13 - Mar. 27, 2020

TCL46-13 (716 downloads)

Conversation with The Cancer Letter
Hollander: Fix telehealth infrastructure—or America will be just as unprepared for the next pandemic
As U.S. health systems switch to telehealth to connect with patients—via phone calls and online video conferencing—during the COVID-19 pandemic, providers are quickly learning that the lack of a national infrastructure for telehealth is making it difficult to reach patients.
Conversation with The Cancer Letter
Knudsen, Flomenberg: Eliminate digital health disparities; we don’t want telemedicine to be for the one-percenters
The Sidney Kimmel Cancer Center at Thomas Jefferson University has been developing a scalable telehealth program long before the spread of SARS-CoV-2 in the United States.
Class of drugs used to treat CAR T-cell toxicity may reduce COVID-19 deaths
Two randomized trials announced
A class of drugs that has been used to treat adverse events associated with CAR T-cell therapy is emerging as a potential treatment for COVID-19.
Conversation with The Cancer Letter
Curigliano: Italy’s COVID-19 cases keep rising; maybe next week the curve will flatten
6,205 health professionals have tested positive and 44 have died
Week after week, Giuseppe Curigliano is waiting to see the first signs of a slowdown in Italy’s cases of COVID-19, and week after week, he is disappointed.
COVID-19 Updates
- ASCO 2020 annual meeting goes virtual
- Congress passes coronavirus relief bill, slating $4.3B for CDC, $3.5B for BARDA, $945M for NIH, $80M for FDA
- NCI on the state of clinical trials, funding
- AACI urges immediate implementation of Defense Production Act
- Nebraska Medicine develops method to reuse personal protective equipment
- Nebraska Medicine infectious disease experts release open-access book on quarantine and isolation
- NSGC urges Congress to recognize genetic counselors
- Breast cancer patient featured in The Cancer Letter receives testing for COVID-19, awaits results
- Resources/FAQs
In Brief
- UCLA, UT Southwestern join NCCN
- S. Michael Rothenberg joins Pfizer Boulder Research Unit
- Kathleen Goss named associate director for administration at University of Chicago Comprehensive Cancer Center
Trials & Tribulations
Against all odds
Unrelated stem cell transplants in coronavirus times
The COVID-19 crisis has consequences not only for those who have become infected and the doctors and nurses who care for them. The care of other patients is also threatened by the increasing stress that national health systems and societies as a whole are under.
Clinical Roundup
- Venclexta combination improves OS in previously untreated AML
- Intense form of radiation slows disease progression in some men with prostate cancer
- Repurposed antidepressant may be a treatment option when prostate cancer comes back, USC study finds

Issue 12 - Mar. 20, 2020

TCL46-12 (818 downloads)

Guest Editorial
The COVID-19 pandemic gives us the urgency—and one more chance—to address health disparities
As the crisis triggered by the COVID-19 pandemic deepens, the two separate, unequal societies that make up the United States of America are equally frightened, bewildered, and unsure of what comes next.
Guest Editorial
ASCO’s Response to COVID-19
The worldwide spread of the coronavirus (COVID-19) presents unprecedented challenges to the cancer care delivery system.
Letter to the Editor
COVID-19 and Cancer Consortium
We are soliciting information under the auspices of a multi-institutional collaboration, the COVID-19 and Cancer Consortium (CCC19).
Sifting through fatality data and projections on COVID-19:
People with cancer, other comorbidities face highest risk
Early data from China and Italy confirm that cancer patients are at higher risk for developing severe adverse events and dying after testing positive for the novel coronavirus.
One cancer patient’s struggle to get a COVID-19 test
“It’s just horrifying that there isn’t a system in place”
The predicament in which Janice Cowden finds herself is so ordinary in today’s pandemic-struck America that it’s repeated thousands of times—and therein lies its horror.
Conversation with The Cancer Letter
Nelson: How Hopkins is managing COVID-19 pandemic
Preparing for a surge in COVID-19 cases this week, the Johns Hopkins health system is relying on the recently-activated Johns Hopkins Medicine Incident Command Center to prioritize the institution’s patient care and research functions and coordinate the opening of testing tents and drive-through testing sites.
Curigliano: “I don’t want to see more people dying”
As COVID-19 deaths rise in Italy, oncologists hope to see the curve flatten
When The Cancer Letter spoke with Giuseppe Curigliano last week, he described the atmosphere in Italy as “spectral” (The Cancer Letter, March 13).
In Brief
- NCCN releases recommendations for standardizing quality measurements in oncology
- UCLA awarded $2.7 million to study AI role in improving cancer diagnosis
- FDA requires new health warnings on cigarette packages, ads
Trials & Tribulations
What community cancer centers need to know about COVID-19
As the incidence of the COVID-19 pandemic increases in U.S. communities, the needs of cancer patients, and those caring for them, are at the forefront of our attention and action.
Clinical Roundup
- Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
- Study suggests link between BMI, nutritional markers, and chemotherapy toxicity in older adults with tumors
- Study: Melanoma is killing fewest Americans
Drugs & Targets
- China accepts sNDA for Zejula in ovarian cancer indication
- The U.K. removes Keytruda from Cancer Drug Fund in bladder cancer indication
- FDA approves Herzuma, equivalent of Herceptin, in indications
- Deaya, Pfizer collaborate on clinical trials

Issue 11 - Mar. 13, 2020

TCL46-11 (761 downloads)

Guest Editorial
COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk
As COVID-19 has now officially been declared a source of the pandemic, with increasing incidence across the nation, it is without question that the needs of patients with particular vulnerabilities should garner particular attention.
Pandemic: Bracing for coronavirus surge
The COVID-19 pandemic will affect every aspect of cancer care and cancer research.
Conversation with The Cancer Letter
Is your cancer center ready for COVID-19?
The Cancer Letter spoke with leaders from the Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, University of California, Los Angeles, and Robert H. Lurie Comprehensive Cancer Center of Northwestern University to gauge the impact of coronavirus.
Conversation with The Cancer Letter
What to expect: Oncology’s response to coronavirus in Italy
“It’s like being in a war”
To get a sense of how COVID-19 will affect oncology in the U.S., The Cancer Letter called Giuseppe Curigliano, associate professor of Medical Oncology at University of Milano and the head of the Division of Early Drug Development at European Institute of Oncology, Italy, who is based in the Lombardy region—the epicenter of the outbreak.
Trials & Tribulations
A conversation about COVID-19: reflecting on first cases in Kansas
The following is a transcript from a weekly Facebook Live program, where Roy Jensen, director of The University of Kansas Cancer Center and Kansas Masonic Cancer Research Institute, interviews cancer researchers, clinicians, and patients.
Clinical Roundup
- FDA encourages inclusion of older adult patients in cancer clinical trials
- Phase III GY004 for Cediranib and Lynparza doesn’t meet PFS endpoint in ovarian cancer indication
- Copper IUDs less likely to contribute to cervical cancer than hormonal IUDs
Drugs & Targets
- FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
- FDA accepts BLA for biosimilar MYL-1402O in cancer indications
- FDA grants Breakthrough Therapy Designation for JNJ-6372 in NSCLC indication
- Thermo Fisher Scientific collaborates with Janssen to co-develop companion diagnostic for cancer
- European Commission approves Venclyxto in CLL indication

Page 6 of 124« First «...2 3 4 567 8 9 10 11...20 30 40 50 60 70 80 90 100 110...»Last »

6,205 health professionals have tested positive and 44 have died

Unrelated stem cell transplants in coronavirus times

“It’s like being in a war”